DK1390474T3 - Fremgangsmåde til opnåelse af antigenspecifikke regulatoriske Tr-1-lymfocytter - Google Patents

Fremgangsmåde til opnåelse af antigenspecifikke regulatoriske Tr-1-lymfocytter

Info

Publication number
DK1390474T3
DK1390474T3 DK02740789T DK02740789T DK1390474T3 DK 1390474 T3 DK1390474 T3 DK 1390474T3 DK 02740789 T DK02740789 T DK 02740789T DK 02740789 T DK02740789 T DK 02740789T DK 1390474 T3 DK1390474 T3 DK 1390474T3
Authority
DK
Denmark
Prior art keywords
lymphocytes
specific regulatory
obtaining antigen
antigen
molecule
Prior art date
Application number
DK02740789T
Other languages
Danish (da)
English (en)
Inventor
Herve Groux
Francoise Cottrez
Abdelilah Wakkach
Original Assignee
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of DK1390474T3 publication Critical patent/DK1390474T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/45—Bacterial antigens
    • A61K40/453—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK02740789T 2001-05-11 2002-05-10 Fremgangsmåde til opnåelse af antigenspecifikke regulatoriske Tr-1-lymfocytter DK1390474T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0106231A FR2824567B1 (fr) 2001-05-11 2001-05-11 Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene
PCT/FR2002/001586 WO2002092793A1 (fr) 2001-05-11 2002-05-10 Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene

Publications (1)

Publication Number Publication Date
DK1390474T3 true DK1390474T3 (da) 2007-07-02

Family

ID=8863160

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02740789T DK1390474T3 (da) 2001-05-11 2002-05-10 Fremgangsmåde til opnåelse af antigenspecifikke regulatoriske Tr-1-lymfocytter

Country Status (10)

Country Link
US (2) US8076133B2 (enExample)
EP (1) EP1390474B1 (enExample)
JP (1) JP4185366B2 (enExample)
AT (1) ATE354641T1 (enExample)
CA (1) CA2446981C (enExample)
DE (1) DE60218302T2 (enExample)
DK (1) DK1390474T3 (enExample)
ES (1) ES2282425T3 (enExample)
FR (1) FR2824567B1 (enExample)
WO (1) WO2002092793A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6358506B1 (en) 1997-11-05 2002-03-19 University Of Southern California Use of cytokines and mitogens to inhibit pathological immune responses
EP1061949B1 (en) 1998-03-03 2009-07-15 University of Southern California Cytokines and mitogens to inhibit graft-versus-host disease
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
CA2469800A1 (en) * 2001-12-21 2003-07-24 University Of Southern California Methods for the induction of professional and cytokine-producing regulatory cells
WO2003057171A2 (en) * 2002-01-03 2003-07-17 The Trustees Of The University Of Pennsylvania Activation and expansion of t-cells using an engineered multivalent signaling platform
US7638326B2 (en) * 2002-01-03 2009-12-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
AU2003292137A1 (en) * 2002-11-29 2004-06-23 Maria Grazia Roncarolo Rapamycin and il-10 for the treatment of immune diseases
FR2852967B1 (fr) * 2003-03-26 2007-12-07 Txcell Procede d'obtention de cellules dendritiques et de cellules t
FR2856700B1 (fr) * 2003-06-24 2007-06-08 Txcell Procede d'identification de lymphocytes tr1 regulateurs par la presence et la surexpression de molecules specifiques et ses applications
WO2005046729A2 (en) * 2003-11-12 2005-05-26 Txcell Use of lipopeptides for activating t lymphocytes through the skin
ES2653570T3 (es) 2004-05-27 2018-02-07 The Trustees Of The University Of Pennsylvania Células presentadoras de antígeno artificiales novedosas y usos de las mismas
US7985409B2 (en) 2004-08-11 2011-07-26 Inserm (Institut National De La Sante Et De La Recherche Medicale) Tr1 cells for use in atherosclerosis
EP1812563B1 (en) * 2004-10-29 2013-04-10 Benaroya Research Institute at Virginia Mason Methods of generating antigen-specific cd4+cd25+ regulatory t cells, compositions and methods of use
EP1712615A1 (en) * 2005-04-15 2006-10-18 Txcell In vitro production of a cell population using feeder cells
EP3130350A1 (en) 2005-06-08 2017-02-15 Dana-Farber Cancer Institute, Inc. Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1)pathway
ATE513903T1 (de) * 2005-07-01 2011-07-15 Txcell S A Herstellung von nahrungsmittel- oder auto-antigen-spezifischen tr1-zellen aus leukozyten oder pbmc
EA015989B1 (ru) * 2005-08-31 2012-01-30 АйТиЭйч ИММЬЮН ТЕРАПИ ХОЛДИНГЗ АБ Лечение воспалительного заболевания кишечника
GB0603081D0 (en) * 2006-02-15 2006-03-29 Dynal Biotech Asa Oslo Method
JP5543207B2 (ja) * 2006-10-04 2014-07-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 不活性化された人工抗原提示細胞の調製および細胞治療におけるそれらの使用
EP2185936A4 (en) * 2007-08-02 2010-08-04 Iss Immune System Stimulation DIAGNOSIS, STADIFICATION AND SURVEILLANCE OF INFLAMMATORY ABDOMINAL DISEASE
JP5539886B2 (ja) * 2007-10-17 2014-07-02 ティクセル Ｔｒ１細胞、間葉系幹細胞およびその使用
EP2050814A1 (en) 2007-10-17 2009-04-22 Txcell Compositions for treating multiple sclerosis
EP2062970A1 (en) * 2007-11-26 2009-05-27 Txcell Compositions for treating an intestinal inflammatory condition
SI2113254T1 (sl) 2008-04-28 2013-01-31 Txcell Sestave za zdravljenje vnetnih avtoimunskih stanj
EP2113560A1 (en) * 2008-04-28 2009-11-04 TXCell Compositions for treating an arthritic condition
CN102282265B (zh) 2008-11-28 2020-07-24 埃默里大学 用于治疗传染病和肿瘤的方法
WO2010077634A1 (en) * 2008-12-09 2010-07-08 Genentech, Inc. Anti-pd-l1 antibodies and their use to enhance t-cell function
EP2221364A1 (en) 2009-02-23 2010-08-25 TXCell Compositions for treating an allergic or asthmatic condition
EP2412802A1 (en) * 2010-07-29 2012-02-01 TXCell IL-13 producing TR1-like cells and use thereof
EP2439534A1 (en) 2010-10-08 2012-04-11 TXCell Method for assessing the efficacy of a TR1 cell therapy in asubject
BR112013023968A2 (pt) 2011-03-25 2016-12-13 Txcell uso de células t reguladoras para a fabricação de medicamentos para tratar condição inflamatória ou autoimune
EP2982746A1 (en) 2014-08-07 2016-02-10 TXCell Regulatory T cells with therapeutic potential
AU2019269601A1 (en) 2018-05-17 2020-11-26 Regents Of The University Of Minnesota Drug-resistant immune cells and methods of use thereof
WO2019237378A1 (zh) * 2018-06-16 2019-12-19 深圳市博奥康生物科技有限公司 一种将CD274基因定点整合至Jurkat细胞的方法及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277635B1 (en) * 1992-03-04 2001-08-21 Schering Corporation Use of interleukin-10 to produce a population of suppressor cells
DE69734974D1 (de) * 1996-02-08 2006-02-02 Us Gov Health & Human Serv Verfahren zur transformation dendritischer zellen und aktivierung von t zellen
CA2254975C (en) * 1996-05-23 2008-12-16 The Scripps Research Institute Mhc class ii antigen-presenting systems and methods for activating cd4+ t cells
US6746670B2 (en) * 2000-08-15 2004-06-08 Schering Corporation Regulatory T cells; methods
US6670146B2 (en) * 2000-10-04 2003-12-30 Schering Corporation Regulatory T cells; methods

Also Published As

Publication number Publication date
EP1390474A1 (fr) 2004-02-25
DE60218302T2 (de) 2007-11-15
JP4185366B2 (ja) 2008-11-26
FR2824567A1 (fr) 2002-11-15
EP1390474B1 (fr) 2007-02-21
US20080233095A1 (en) 2008-09-25
CA2446981C (fr) 2012-03-20
DE60218302D1 (de) 2007-04-05
ES2282425T3 (es) 2007-10-16
US8076133B2 (en) 2011-12-13
ATE354641T1 (de) 2007-03-15
FR2824567B1 (fr) 2003-08-08
WO2002092793A1 (fr) 2002-11-21
JP2004526459A (ja) 2004-09-02
US20040191235A1 (en) 2004-09-30
CA2446981A1 (fr) 2003-11-21

Similar Documents

Publication Publication Date Title
DK1390474T3 (da) Fremgangsmåde til opnåelse af antigenspecifikke regulatoriske Tr-1-lymfocytter
JP2004526459A5 (enExample)
DK0828717T3 (da) Fremgangsmåde til fremstilling af 3-haloalkyl-1H-pyrazol
AU2999199A (en) Mesenchymal stem cells as immunosuppressants
DE69942100D1 (de) Künstliche antigen-spezifischen zellen und zugehörige verfahren
MXPA05000655A (es) Metodos y composiciones para modular el desarrollo y la funcion de las celulas t helper (th).
DK1194580T3 (da) In vitro-rekonstruktion af segmenterede negativ-strengede RNA-virus
PL2327763T3 (pl) Generowanie komórek T specyficznych względem antygenu
MXPA01007810A (es) Plataforma para la diferenciacion de celulas.
WO2003038062A3 (en) Generation of use of tc1 and tc2 cells
IL168921A (en) A method for creating a plant that includes plant cells @ conserved
WO2002076032A3 (de) Verfahren und vorrichtung zur erstellung eines zeitplans der übermittlung von nachrichten auf einem bussystem
AU5211200A (en) Method for diminishing specific immune reactions
DE60039913D1 (de) Methoden um die bindung einer cd8+ zelle an einen class i mhc zu inhibieren,unter verwendung eines modifizierten beta 2 microglobulins
WO1997011669A3 (en) MHC-class II restricted melanoma antigens and their use in therapeutic methods
ATE254137T1 (de) ßLIGAND PRESENTING ASSEMBLYß (LPA), VERFAHREN ZU DESSEN HERSTELLUNG UND VERWENDUNGEN
ATE246250T1 (de) Immunogenes konstrukt, verfahren zu dessen herstellung und verwendung als vakzine
DE59608343D1 (de) Geschlossenporige Siliconschäume, Verfahren zu ihrer Herstellung und ihre Verwendung
NO985739L (no) Generering av molekyler som er replikative in vivo
BR9910153A (pt) ácido nucléico e polipeptìdeos de cd80 de felino, cd80 de felino, cd28 de felino e ctla-4 de felino
Kantrowitz et al. We've seen the future: It's in Iowa.
AU1848401A (en) A novel method to produce human natural interferon-alpha
SE9901110D0 (sv) Artificial vision method and system
Tullo LOSA shows promise to help increase air safety
Watkins-Miller Bright savings.